BOW 060

Drug Profile

BOW 060

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EPIRUS Biopharmaceuticals
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Inflammation

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 22 May 2015 Discontinued - Preclinical for Cancer in USA (IV)
  • 22 May 2015 Discontinued - Preclinical for Inflammation in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top